Catalyst Science Discovery Centre appoints director

Widnes, Cheshire-based firm welcomes Stephen Youd-Thomas

Catalyst Science Discovery Centre, an interactive science centre and museum devoted to chemistry and how the products of chemistry are used in everyday life based in Widnes, Cheshire, UK, has a new director of catalyst, which encompasses the role of ERDF project director.

Stephen Youd-Thomas runs a successful corporate and social responsibility consultancy and was formerly head of social goals at the Co-operative Group.

‘This is a wonderful opportunity to help develop the work of the UK's only science discovery centre with chemistry as its main theme. Catalyst brings chemistry alive for thousands of young people from across the North West and beyond and hopefully this experience will encourage many of them to consider a career in science in the future,’ he said.

Catalyst is an independent charitable trust operated by Catalyst Science Discovery Centre and Museum Trust.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Autoinjector platforms: optimising device selection and unlocking manufacturing efficiency for injectable pipelines

Owing to ageing populations, the increased prevalence of chronic disease and additional pressure on global healthcare systems, among other factors, the market for drug delivery devices for self-administration (autoinjectors) is growing
Ingredients

Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt

Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence

OMass and Genentech to develop and commercialise therapies for inflammatory bowel disease

The collaboration leverages OMass’ Odyssion platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Debunking the myths of HPMC adoption

Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
Drug Delivery

Breaking barriers: enhancing the bioavailability of orally delivered TPDs

It’s been said that nothing vast enters the realm of mortals without a curse. Such is the case with targeted protein degraders (TPDs), now one of the fastest-growing frontiers in oral solid dose pharmaceuticals
Subscribe now